Rationale: Fibroblast growth factor homologous factors (FHFs), a subfamily of fibroblast growth factors (FGFs) that are incapable of functioning as growth factors, are intracellular modulators of Na ؉ channels and have been linked to neurodegenerative diseases. Although certain FHFs have been found in embryonic heart, they have not been reported in adult heart, and they have not been shown to regulate endogenous cardiac Na ؉ channels or to participate in cardiac pathophysiology.
T he four fibroblast growth factor homologous factors (FHFs), a subset of the fibroblast growth factor (FGF) family, have received increasing attention for their unanticipated modulation of neuronal voltage-gated Na ϩ channels (VGSCs) and regulation of neuronal excitability. Although FHFs are potentially important regulators of cardiac VGSCs, the function of FHFs in cardiac myocytes has not been investigated and would provide insight into arrhythmogenesis caused by changes in sodium channel function. FHFs were originally named because of their similarity to FGFs, but several defining features of the FHFs (FGF11, FGF12, FGF13, and FGF14) set them apart from other FGFs. 1 First, only the central core domain of each FHF shares homology with the FGF superfamily. 1 Outside of this core domain, FHFs have extended N-termini and C-termini compared to FGFs. For each FHF, these N-termini, encoded by alternatively spliced first exons, provide significant diversity. 2 An additional feature distinguishing them from FGFs is that FHF N-termini lack signal sequences and FHFs thus are not secreted. Whereas other nonsecreted FGFs, such as FGF-9, are released after cell damage and activate cell surface FGF receptors on target cells, FHFs are incapable of stimulating FGF receptors. 3 Thus, FHFs do not function as secreted growth factors or morphogens. Rather, these intracellular proteins bind to the intracellular C-termini of VGSCs and modulate channel function. 4 All FHFs are expressed most abundantly in the brain, 1 and several loss-of-function mutations have established FGF14 as the locus for spinocerebellar ataxia 27. [5] [6] [7] [8] The prototypical spinocerebellar ataxia 27 mutant FGF14 F145S reduces Na ϩ channels at the axon initial segment, diminishes Na ϩ currents (I Na ), and dampens excitability in a dominant-negative manner when expressed in cultured hippocampal neurons. 8 Although not yet investigated, analogous regulation of cardiac Na ϩ channels by FHFs and dysregulation by mutant FHFs could underlie cardiac physiology and pathophysiology, respectively. Na ϩ channel dysfunction is central to various inherited arrhythmias such as long QT syndrome and Brugada syndrome. FHF regulation of extraneuronal Na channels has received little attention, however, despite evidence that certain FHF family members are expressed in the heart 2 and that FGF12 and FGF14 can modulate gating kinetics of the cardiac Na ϩ channel Na V 1.5 in a heterologous expression system. 9, 10 Whether FHFs affect Na V 1.5 in cardiac myocytes and whether loss of function alters myocyte excitability has not been addressed. Further, certain FHFs appear to interact with only a subset of VGSCs, 9 suggesting the need for analyzing specific FHFs in the context of the VGSC expressed in a specific cell type.
Here, we investigated whether FHFs are capable of modulating sodium current (I Na ) in adult mouse ventricular myocytes. We show that specific FGF13 isoforms are the major FHFs expressed in mouse heart and that they can bind to and modulate cardiac Na V 1.5 Na ϩ channel function and membrane expression, leading to changes in cardiac conduction properties. This work identifies FHFs as potent modulators of cardiac I Na and suggests FHF-mediated dysregulation of I Na may have proarrhythmic effects in heart.
Methods

Mice and Rats
Animals were handled according to National Institutes of Health Guide for the Care and Use of Laboratory Animals. The study was approved by Duke University Animal Care and Welfare Committee.
Glutathione S-Transferase Pull-Down
The human Na V 1.5 C-terminus (aa 1773 to 2018) was fused to glutathione S-transferase (GST) in pGEX-4T. Optical mapping of action potential propagation was performed as described. 12, 13 Electrophysiology I Na in adult mice ventricular myocytes were recorded using the whole-cell patch clamp technique as previously described. 14 -16 
Statistical Analyses
Results are presented as meansϮstandard error; the statistical significance of differences between groups was assessed using either a two-tailed Student t test or one-way analysis of variance and was set at PϽ0.05.
Results
We investigated which FHF transcripts were most abundant in the adult mouse heart. To exclude contamination by neuronal FHFs, we used isolated adult mouse ventricular myocytes. Various alternatively spliced FGF11 and FGF13 transcripts were previously identified in both embryonic and adult mouse heart, 2 but their relative expression levels have not been assessed. We therefore designed a quantitative reverse-transcriptase polymerase chain reaction (qPCR) strategy with isoform-specific primers ( Figure 1A and Supplemental Table I ) to define the relative expressions levels of all FHF isoforms in isolated adult mouse ventricular myocytes. As seen in Figure 1B , FGF13-VY was most abundant and other FGF13 isoforms were expressed at lower levels, except for FGF13-U, which was barely detectable. Transcripts for FGF11, FGF12, and FGF14-A were also expressed at very low levels; the level of message for FGF14-B was detectable, Figure 1C , only FGF13 was detected by immunoblot using a novel polyclonal antibody (Supplemental Figure IA) . The FGF13 in heart migrated at Ϸ29 kDa, consistent with molecular weight of the FGF13-VY variant that was most abundant by qPCR. To confirm that the FGF11, FGF12, and FGF14 antibodies were capable of detecting endogenous FHFs, we immunoblotted lysates from whole brain and observed that all four FHFs were detectable ( Figure 1C ). The relative abundance of FHF proteins in brain was consistent with their respective mRNA levels, as quantified by qPCR (Supplemental Figure II) . In brain, the FGF13 antibody detected a band that migrated faster than the band observed in lysates from ventricular cardiomyocytes. Consistent with that pattern, qPCR for FGF13 variants in mouse brain showed that the FGF13-S isoform (predicted molecular weight of 27.6 kDa) was the most abundant FGF13 mRNA. The use of different antibodies, each of which has its distinct affinity for its specific target, precludes a direct quantitative assessment of protein abundance. Nevertheless, the correlations between protein abundance by immunoblot and mRNA expression by qPCR in both brain and heart suggest that FGF13 is the most abundant FHF in heart, and any FHF regulation of cardiac Na ϩ channels in adult mouse ventricular myocytes would be mediated predominantly by FGF13 isoforms. Although previous heterologous expression system data have suggested that FGF12 and FGF14 are capable of modulating Na V 1.5, 9,10 we concentrated our subsequent studies exclusively on FGF13.
To characterize FGF13 in ventricular myocytes, we generated a polyclonal antibody against a peptide in the C-terminus of FGF13 designed to recognize all FGF13 isoforms (Supplemental Figure IA) . The antibody was specific for FGF13, recognizing FGF13-VY expressed in tsA201 cells but not FGF12 or FGF14, as shown in Supplemental Figure IB . Having demonstrated the antibody's specificity, we tested for the presence of FGF13 in isolated adult mouse ventricular myocytes. Figure 2A shows an immunoblot in which the FGF13 antibody recognizes a major band of Ϸ29 kDa (predicted molecular weight for FGF13-VY is 28.8 kDa). A fainter band is apparent at Ϸ26 kDa, which could represent a degradation product, FGF13-V or FGF13-Y (predicted molecular weight for FGF13-V and FGF13-Y are 22.3 and 25.6 kDa, respectively). These bands are likely specific because no signals were observed after addition of the immunizing peptide to the antibody (Figure 2A , right lane). The FGF13 antibody was also able to coimmunoprecipitate Na V 1.5 from isolated mouse ventricular myocyte lysates ( Figure 2B ), suggesting that FGF13 and Na V 1.5 are in the same complex. No Na V 1.5 was coimmunoprecipitated with a control IgG antibody. This interaction was likely direct, as indicated by pull-down experiments with GST fusion proteins. A GST fusion protein containing the Na V 1.5 C terminus, but not the GST control protein, pulled-down the His6-tagged FGF13-VY from lysates of transiently transfected tsA201 cells ( Figure 2C ); the Na V 1.5 CT also pulleddown recombinant versions of all the FGF13 isoforms (not shown), suggesting a common site of interaction-the FGF13 core-consistent with studies of other FHF/Na V 1.x interactions. 17 Thus, FGF13 isoforms bind directly to the Na V 1.5 C-terminus. Immunostaining experiments were performed to assess the expression pattern in single ventricular myocytes and ventricular tissues. Immunocytochemistry on isolated adult mouse ventricular myocytes showed FGF13 colocalized with Nav1.5 at the lateral membrane and intercalated discs ( Figure  2D , left panels), which was verified by costaining with the known marker, ankyrin-G ( Figure 2D , right panels). 18 We also noted FGF13 in the nucleus and cytoplasm, which has been previously described in COS cells. 2 Immunohistochemistry on adult mouse ventricle demonstrated no overt transmural gradients of FGF13 in left (Supplemental Figure III) and right ventricles (not shown).
To evaluate the role of endogenous FGF13 in the regulation of cardiac I Na , we knocked down FGF13 in isolated mouse ventricular myocytes with an adenovirus expressing both a shRNA targeting all FGF13 isoforms and GFP (to identify transfected cells). An adenovirus expressing a scrambled shRNA with GFP was used as a control. Viral infection itself did not affect FGF13 expression as shown by the two myocytes infected with adenovirus expressing a scrambled sequence ( Figure 3A , top panels); the level of FGF13 and its overall cellular pattern are similar in the infected cell (as indicated by GFP) and the adjacent noninfected cell (GFPnegative). In contrast, immunostaining with the FGF13 antibody showed that the FGF13 shRNA markedly reduced FGF13 expression compared to control (uninfected) cells or cells infected with a scrambled shRNA ( Figure 3A , bottom panels). Almost no sarcolemmal membrane or cytoplasmic FGF13 was visible after shRNA knockdown, although a minor amount of nuclear FGF13 remained. Efficacy of knockdown by the shRNA was also analyzed by qPCR, which showed 90%Ϯ3% (PϽ0.01) reduction in FGF13 mRNA compared to a scrambled control shRNA ( Figure 3B ), and by immunoblot, which showed 92%Ϯ2% (PϽ0.01) reduction in FGF13 protein ( Figure 3C, D) . Moreover, these data confirmed the specificity of the shRNA because FGF12 mRNA levels were unaffected ( Figure 3B ). Having demonstrated the efficiency of knockdown by FGF13 shRNA, I Na was recorded and analyzed in single adult ventricular myocytes infected with FGF13 shRNA, scrambled shRNA, or no treatment control. Figure 3E shows representative families of wholecell I Na in cardiomyocytes recorded from a holding potential of Ϫ120 mV to test potentials between Ϫ100 mV and ϩ60 mV in 5-mV increments. Whereas mean whole-cell capacitance was not significantly altered after FGF13 knockdown, peak current density, measured at Ϫ30 mV, was reduced by 49%Ϯ4% (PϽ0.01; Table and Figure 3E , F) compared to cells treated with scrambled shRNA or untreated controls.
To determine the mechanisms by which FGF13 knockdown reduced current density in myocytes, we investigated whether FGF13 affected the amount of Na V 1.5 at the sarcolemma, altered Na V 1.5 gating kinetics, or both. To evaluate the amount of Na V 1.5 at the sarcolemma, we labeled cellsurface proteins in isolated myocytes with biotin, lysed the myocytes, and captured biotinylated proteins with NeutrAvidin beads. Sarcolemmal Na V 1.5 was then quantified by immunoblot using an anti-Na V 1.5 antibody. Transferrin receptor, an endogenous plasma membrane protein, was used to normalize sarcolemmal Na V 1.5 among different experiments, 19 and GAPDH was used for normalizing total Na V 1.5 protein levels. The fractionation was effective because no GAPDH was detected among the biotinylated proteins (not shown). An exemplar experiment is shown in Figure 4A . Quantification of three independent experiments ( Figure 4B ) revealed that knockdown of FGF13 had no effect on the total amount of Na V 1.5 in the myocyte lysate (99%Ϯ8% of control; PϾ0.05) but reduced surface Na V 1.5 by 45%Ϯ5% (PϽ0.01 compared to control). In contrast to effect on surface Table I ) and FGF12B mRNA levels by quantitative polymerase chain reaction (qPCR) in uninfected cultured myocytes (control) or those infected with scrambled shRNA (scrambled) or FGF13 shRNA (shRNA). All data were corrected with GAPDH and normalized to control. **PϽ0.01 compared to control; nϭ6 for FGF13 and nϭ3 for FGF12-B. C, Representative immunoblot of FGF13 protein expression in isolated control myocytes, or myocytes infected with scrambled or shRNA. Result is representative of three independent experiments. D, Histograms showing normalized amounts of FGF13 protein from control, scrambled, or shRNA treated myocytes. **PϽ0.01 compared to control; nϭ3. GAPDH was used as loading control. E, Exemplar Na ϩ channel current traces elicited by 40-ms depolarizing pulses to test potentials between Ϫ100 mV and ϩ60 mV from a holding potential of Ϫ120 mV at 5-mV increments (interpulse interval, 3 seconds). Inset shows schematic of the voltage clamp protocol. F, MeansϮstandard error of the mean of maximum peak Na ϩ channel current density measured at Ϫ30 mV in control, scrambled, or shRNA-infected myocytes. Numbers of cells tested are shown inside of each column. **PϽ0.01 compared to control. Na V 1.5 protein levels, FGF13 knockdown did not alter Na V 1.5 mRNA levels, which were assessed by qPCR ( Figure  4C ). Together, these data suggest that FGF13 knockdown reduced current density by specifically reducing sarcolemmal Na V 1.5 without affecting channel transcription or translation.
To assess whether the reduction in current density after FGF13 knockdown also might be attributable to effects on channel gating kinetics, we analyzed Na ϩ channel activation, inactivation, and recovery from inactivation in isolated ventricular myocytes. Activation was unaffected by FGF13 knockdown as shown in Figure 4D . Steady-state inactivation was determined using a standard double-pulse protocol and the data were fitted by a Boltzmann equation (Figure 4E , Table) . Knockdown of FGF13 resulted in a hyperpolarized shift in steady-state I Na inactivation, indicating that the fraction of available Na ϩ channels was reduced at membrane potentials more depolarized than ϷϪ110 mV. Because the decrease in availability was significant at holding potentials near the resting membrane potential of a ventricular myocyte (ie, ϷϪ90 mV), we analyzed how much the contribution of decreased availability contributed to the reduction in current density at a holding potential of Ϫ90 mV compared to Ϫ130 mV, where availability was unaffected ( Figure 4F ,G, Table) . We found that FGF13 knockdown decreased current density by Ϸ50% (10.3Ϯ0.9 pA/pF vs 20.3Ϯ2.1 pA/pF; PϽ0.01) when the myocytes were held at Ϫ130 mV, consistent with the observed reduction in Na V 1.5 protein at the sarcolemma ( Figure 4B ). In contrast, when myocytes were held at Ϫ90 mV, FGF13 knockdown reduced current density by 72% (3.5Ϯ0.5 pA/pF vs 12.3Ϯ2.5 pA/pF; PϽ0.01), suggesting that current density was decreased not only by the reduced amount of Na V 1.5 at the sarcolemma but also by reduced channel availability. Knockdown of FGF13 also delayed channel recovery from inactivation ( Figure 5 , Table) . Double exponential fits showed that the fast and slow components were significantly slowed compared to control myocytes or myocytes treated with scrambled shRNA (Table) . Because I Na completely recovered within Ͻ200 ms in cardiomyocytes of either group, the interpulse interval (3 seconds) used in the protocols for activation and inactivation was sufficiently long to allow complete recovery. However, the delayed recovery from inactivation in FGF13 knockdown myocytes predicts that at elevated heart rates the insufficient time for recovery would reduce sodium channel availability and thus decrease excitability and slow cardiac conduction.
We therefore tested whether FGF13 knockdown in myocytes affected cardiac conduction properties. We knocked down FGF13 in neonatal rat ventricular myocyte monolayers cultured on fibronectin and analyzed conduction velocity and maximum capture rate by optical mapping. 9, 10 As shown in Figure 6A and 6C, conduction velocity was markedly slowed in monolayers after FGF13 knockdown (9.7Ϯ1.3 cm/s; PϽ0.001) compared to control monolayers (18.9Ϯ1.1 cm/s) or monolayers infected with the scrambled shRNA (16.7Ϯ1.0 cm/s). Action potential duration ( Figure 6B, D) was unaffected (206.7Ϯ7.7 ms, 189.1Ϯ9.7 ms, and 206.8Ϯ11.4 ms for control, scrambled, and shRNA, respectively; PϾ0.05 compared to control). Maximum capture rate, defined as the maximum rate at which a 1:1 response of monolayers was maintained for at least 30 seconds of pacing, was significantly reduced after FGF13 knockdown (4.6Ϯ0.2 Hz, 4.7Ϯ0.2 Hz, and 3.3Ϯ0.2 Hz for control, scrambled shRNA, and FGF13 shRNA, respectively; PϽ0.001 compared to control; Figure  6E ). Taken together, these data suggest that FGF13 knockdown is associated with abnormal cardiac conduction properties because of reduced Na ϩ channel current density and delayed recovery from inactivation.
Discussion
This is the first report to our knowledge demonstrating that FHFs affect VGSCs in cardiac myocytes. Although FHFs have well-documented effects on VGSCs in neurons and FGF14 is the locus for spinocerebellar ataxia 27, 5,8,20 -24 whether FHFs operate within cardiac myocytes and any consequential effects of FHF actions within myocytes have not been investigated. Whereas previous reports demonstrated that certain FHFs (FGF12 and FGF14) were capable of modulating Na V 1.5 in heterologous expression systems, 9,10 this study demonstrates how endogenous FHFs modulate VGSCs in cardiac myocytes.
We showed that FGF13 is the major FHF in mouse ventricular myocytes and that it has critical roles in modulation of Na V 1.5 channel function and membrane expression in myocytes. Knockdown of FGF13 decreased Na V 1.5 at the sarcolemma and decreased Na ϩ channel availability at holding potentials near the ventricular myocyte resting potential. The combined effects produced a marked reduction in Na ϩ channel current density. These results suggest that loss-offunction mutations in cardiac FHFs may be unrecognized causes of cardiac disorders associated with Na ϩ channel loss of function. Consistent with our data obtained in isolated V 1/2 of activation (mV) Ϫ44.9Ϯ0.6 (7) Ϫ45.0Ϯ0.5 (7) Ϫ43.9Ϯ0.5 (7) k of activation (mV) 6.1Ϯ0.4 (7) 5.7Ϯ0.4 (7) 6.3Ϯ0.3 (7)
k of inactivation (mV) I Na indicates sodium current; C m , membrane capacitance; R s , series resistance.
The number of cells analyzed for each parameter is provided in parentheses. *PϽ0.05 compared to control. †PϽ0.01 compared to control.
myocytes, we found that conduction velocity was reduced in neonatal cardiomyocyte monolayers using optical mapping. Although it is likely that this is a result of the reduced current density or channel availability seen in the single cell experiments, we cannot exclude other mechanisms such as changes in gap junction properties. Additionally, optical mapping showed a significant decrease in maximum capture rate, likely because of the observed slowing of Na ϩ channel recovery from inactivation. Together, these results suggest that loss-of-function mutations in cardiac FHFs may be proarrhythmic by lowering the threshold of heart rate for which Na ϩ channels can fully recover and decreasing conduction velocity and maximum capture rate, thereby providing a substrate for re-entrant arrhythmias. Slowed conduction, attributable to mutations in Na V 1.5, is a hallmark of Brugada syndrome, 25 suggesting that FHFs may be unrecognized and unexplored Brugada syndrome loci, for which identified loci explain only Ϸ30% of patients. Whereas no human mutations in an FHF have yet been associated with an inherited arrhythmia or conduction disorder, our data provide evidence that FHFs might join the growing list of members in the recently coined "sodium channelsome" in the heart 26 in which mutations in modulators affect cardiac Na ϩ channel function and thereby cause a similar set of disorders attributed to mutations in the channels themselves.
Our data provide other mechanistic insights into how FGF13 regulates cardiac I Na . In addition to affecting channel gating, we observed that FGF13 increases the amount of channel at the sarcolemma without affecting Na V 1.5 transcription or translation. This appears analogous to the role that FHFs play in Figure 4 . Knockdown of FGF13 by shRNA decreases cell surface Na ؉ channel levels and reduces channel availability in adult mouse ventricular myocytes. A, Representative cell surface biotinylation experiment showing total Na V 1.5 (total lysate, top panels) and biotinylated Na V 1.5 (membrane fraction, bottom panels) in control, scrambled, and FGF13 shRNA-infected myocytes. GAPDH and transferrin receptor (TfR) were used as loading control for whole lysate and membrane fraction, respectively. No GAPDH was detected in the biotinylated fraction (not shown). Results are representative of three independent experiments. B, Histograms showing the normalized amounts of total Na V 1.5 protein (total lysate) or biotinylated Na V 1.5 protein (membrane fraction) in myocytes of control, scrambled, or shRNA. Data were corrected with the loading control (GAPDH or TfR for total lysate or membrane fraction, respectively). **PϽ0.01 compared to control. nϭ3. C, Quantitative analysis of Na V 1.5 mRNA by quantitative polymerase chain reaction (qPCR) in control, scrambled, and shRNA-infected myocytes. All data were corrected with GAPDH and normalized to control. **PϽ0.01 compared to control; nϭ6. D, Voltage dependence of steady-state activation. E, Voltage dependence of steady-state inactivation. See Table for response to voltage commands consisting of two Ϫ30-mV depolarization pulses (P 1 and P 2 ) from a holding potential of Ϫ120 mV, separated by a 1-to 200-ms variable interpulse interval (P 1 -P 2 interval) at Ϫ120 mV. The pulse protocol cycle time was 3 seconds. B, Normalized I Na recovery (P 2 /P 1 ) vs interpulse interval at Ϫ120 mV in control, scrambled, and shRNA-infected myocytes. Mean data were fitted by a double exponential and time constants of recovery are summarized in Table. Pulse protocol is shown in inset.
targeting VGSCs to the axon initial segment of neurons, 1, 2 suggesting that regulation of VGSC trafficking by FHFs may be widespread and may open an interesting avenue for future investigation in the field of channel trafficking. Our coimmunoprecipitation and GST pull-down experiments suggest that FGF13 interacts directly with Na V 1.5, as has been reported for other FHF-Na V 1.x pairs. This direct binding is likely responsible for the effects of FGF13 on channel kinetics, as we recently demonstrated. 27 Whether regulation of trafficking also requires direct interaction between FHFs and Na V 1.x C-termini is not known, but a previous report suggests that Na V 1.x C-termini are hot spots for regulation of channel trafficking through their binding partners (membrane localization of Na V 1.1 was augmented by calmodulin, a G-protein ␤␥ complex, and a sodium channel ␤ subunit, all of which interact with the channel's C-terminus 28 ; and a FGF14 spinocerebellar ataxia 27-causing mutant, which abolished binding of that FHF to Na V 1.2, reduced targeting of VGSCs to the axon initial segment 8 ) or because of the C-termini themselves (the Y1795H mutation in Na V 1.5 reduces current density, whereas Y1795C has increases current density 29 ) . Whether any or all of these binding partners are concurrently associated with a Na V 1.x C-terminus and thereby confer an integrated form of regulation is not yet known.
We cannot exclude the possibility that FGF13 modulates the channel through other means that we have not explored. The widespread cellular distribution of FGF13 hints at other roles for FGF13 in cardiomyocytes, including the modulation of other cardiac ion channels. Of particular interest is prominent nuclear localization of a portion of FGF13, previously seen for other FHF isoforms in heterologous expression systems. 8, 10 Further, the punctate distribution throughout the cytoplasm suggests that FGF13 plays additional roles in myocyte yet to be described. Those roles may be revealed when a FGF13 knockout model becomes available. Whereas this study characterizes the expression pattern and role of FGF13 in ventricular cardiomyocytes, we did not assess the levels of FGF13 mRNA or protein in the atria or the conduction system. It is possible that different FHFs predominate in other areas of the myocardium and confer different roles.
A significant contribution of this study is that the analyses were performed in cardiac myocytes. Previous experience with other FHFs have shown that data derived from heterologous expression systems do not necessarily reveal the functions of endogenous FHFs in native cell types. Thus, the biochemistry and cellular electrophysiology reported here help advance the understanding of FHF regulation of I Na within cardiac myocytes. Data were obtained during 1-Hz point electrode stimulation (white pulse sign, ⌸). C to E, Calculated average conduction velocity, average action potential duration measured at 80% repolarization (APD 80 ), and average maximum capture rate, respectively. **PϽ0.001 compared to control; nϭ8, 7, and 9 for control, scrambled, and shRNAinfected myocytes, respectively.
